研究单位：[1]Peking Union Medical College Hospital[2]Obstetrics & Gynecology Hospital of Fudan University[3]Shengjing Hospital[4]Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University[5]Henan Cancer Hospital[6]Gansu Provincial Maternal and Child Health Care Hospital[7]Dalian Maternity and Child Care Hospital[8]The First Affiliated Hospital of Xiamen University[9]Sichuan Cancer Hospital & Institute[10]Shanghai Junshi Bioscience Co., Ltd.[11]Peking Union Medical College Hospital,Beijing,Beijing,China,100730
The goal of this clinical trial is to evaluate the efficacy and safety of toripalimab plus actinomycin-D as fist-line treatment in patients with gestational trophoblastic neoplasia with FIGO score 7. The main questions it aims to answer are: - Whether toripalimab plus actinomycin-D as fist-line treatment can achieve a high complete response rate. - Whether an equally high cure rate can be achieved by multi-drug chemotherapy as second-line treatment in patients who have failed fist-line treatment with toripalimab plus actinomycin-D. Participants will receive toripalimab plus actinomycin-D. Treatment will be continued until disease progression, unacceptable toxicity, or withdrawal of consent. Treatment will be completed after 4 consolidation cycles.
